ctDNA clearance: a promising early signal, not yet a definitive endpoint

The article argues that ctDNA clearance—when tumor-derived DNA that was detectable in a blood sample becomes undetectable—could give drug developers an early signal that treatment is working, sometimes before scans or longer-term outcomes are available.

That signal may help trials identify high-risk patients earlier, test treatments when disease burden is low, and support quicker decisions about whether a drug merits further development. In some studies, early clearance has been associated with better survival or disease-free outcomes.

But “undetectable” is not the same as proof that cancer is gone. Results depend on assay sensitivity, tumor type, and when blood is collected; a negative result can reflect levels below the test’s detection limit. Clearance also overlooks patients whose ctDNA falls substantially but remains detectable.

The main development implication is promise, not settled practice:
ctDNA is increasingly used for risk selection and early response assessment, but it has not been established as a universally validated surrogate for clinical benefit in solid tumors. Trials still need prospective evidence and consistent measurement methods.

A recent sponsored overview cited an example in which day-45 MRD-clearance data in Allogene Therapeutics’ ALPHA3 study helped support FDA RMAT and Fast Track designations for cema-cel. Those designations are not proof of efficacy or approval.